Tony Coles
CEO
Cerevel

Dr. Coles is executive chairman and chief executive officer of Cerevel Therapeutics, a Bain-portfolio biotechnology company specializing in the development of new therapies for diseases of the central nervous system. Dr. Coles is a founding investor and the chairman of Yumanity Therapeutics, a Cambridge, MA-based biotechnology company focused on transforming drug discovery for neurodegenerative diseases.Dr. Coles also serves as chairman and chief executive officer of TRATE Enterprises, LLC, a privately held company.Previously, Dr. Coles was chairman and chief executive officer of Onyx Pharmaceuticals, Inc. Prior to joining Onyx in 2008, he was president, chief executive officer and a member of the board of directors of NPS Pharmaceuticals, Inc. Before joining NPS Pharmaceuticals in 2005.Educated at Johns Hopkins University,earned a medical degree from Duke University and a master’s degree in public health from Harvard University. He completed his cardiology and internal medicine training at Massachusetts General Hospital and was a research fellow at Harvard Medical School.Dr. Coles currently serves on the board of directors of McKesson Corporation and Regeneron (NASDAQ: REGN) and is a member of the board of trustees for Johns Hopkins University and Johns Hopkins Medicine. Dr. Coles is also a member of the Council for the Smithsonian’s National Museum of African American History and Culture in Washington, D.C.; a member of the board of trustees for The Metropolitan Museum of Art in New York City; a member of the board of directors of the Council on Foreign Relations, an independent, nonpartisan membership organization, think tank, and publisher; and a member on the Harvard Medical School Advisory Board.